Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CARA Stock Forecast 2025-2026
$15.96
Current Price
$8.11M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CARA Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CARA Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-39.6%
1 Year Change
-13.1%
Year-to-Date Change
-49.0%
From 52W High of $31.32
+96.4%
From 52W Low of $8.13
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Cara Therapeutics (CARA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CARA and similar high-potential opportunities.
Latest CARA Stock Price Targets & Analyst Predictions
CARA has shown a year-to-date change of -13.1% and a 1-year change of -39.6%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CARA. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CARA Analyst Ratings
0
Buy
1
Hold
0
Sell
CARA Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $15.96
Latest CARA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CARA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 13, 2024 | Needham | Joseph Stringer | Hold | Downgrade | $0.00 |
| Jun 13, 2024 | HC Wainwright & Co. | Oren Livnat | Neutral | Downgrade | $0.00 |
| Jun 13, 2024 | Canaccord Genuity | Sumant Kulkarni | Hold | Downgrade | $1.00 |
| May 23, 2024 | Needham | Buy | Reiterates | $0.00 | |
| May 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| May 14, 2024 | Needham | Buy | Reiterates | $0.00 | |
| Apr 10, 2024 | Needham | Buy | Reiterates | $0.00 | |
| Mar 6, 2024 | Canaccord Genuity | Buy | Maintains | $0.00 | |
| Mar 5, 2024 | Needham | Buy | Reiterates | $0.00 | |
| Jan 22, 2024 | Needham | Buy | Maintains | $0.00 | |
| Dec 19, 2023 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| Dec 18, 2023 | Needham | Buy | Maintains | $0.00 | |
| Nov 14, 2023 | Piper Sandler | Neutral | Downgrade | $0.00 | |
| Oct 19, 2023 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| Aug 8, 2023 | Needham | Buy | Reiterates | $0.00 | |
| Aug 8, 2023 | Piper Sandler | Overweight | Maintains | $0.00 | |
| Jun 27, 2023 | Jefferies | Buy | Reiterates | $0.00 | |
| Jun 27, 2023 | Stifel | Buy | Reiterates | $0.00 | |
| May 16, 2023 | B of A Securities | Underperform | Maintains | $0.00 | |
| May 16, 2023 | HC Wainwright & Co. | Buy | Maintains | $0.00 |
Cara Therapeutics, Inc. (CARA) Competitors
The following stocks are similar to Cara Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cara Therapeutics, Inc. (CARA) Financial Data
Cara Therapeutics, Inc. has a market capitalization of $8.11M with a P/E ratio of -1.0x. The company generates $7.14M in trailing twelve-month revenue with a 91.3% profit margin.
Revenue growth is -51.6% quarter-over-quarter, while maintaining an operating margin of -412.4% and return on equity of -270.0%.
Valuation Metrics
Market Cap
$8.11M
Enterprise Value
$30.88M
P/E Ratio
-1.0x
PEG Ratio
-6.9x
Price/Sales
1.1x
Growth & Margins
Revenue Growth (YoY)
-51.6%
Gross Margin
+100.0%
Operating Margin
-412.4%
Net Margin
+91.3%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+155.8%
Current Ratio
11.0x
Debt/Equity
-9.7x
ROE
-270.0%
ROA
-41.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Cara Therapeutics, Inc. (CARA) Business Model
About Cara Therapeutics, Inc.
What They Do
Develops therapeutics for chronic pruritus.
Business Model
Cara Therapeutics generates revenue primarily through the development and commercialization of its lead product, KORSUVA, for treating chronic pruritus related to chronic kidney disease. The company also engages in licensing agreements with various pharmaceutical companies to expand the reach and application of its drug products in different markets, enhancing its potential revenue streams.
Additional Information
Founded in 2004 and based in Stamford, Connecticut, Cara Therapeutics is actively advancing its pipeline, including an oral formulation of its lead drug that is currently in clinical trials. The company's strategic partnerships with firms like Maruishi Pharmaceutical and Vifor Fresenius bolster its market presence in Japan and other regions, indicating a solid growth potential.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
10
CEO
Mr. Christopher A. Posner
Country
United States
IPO Year
2014
Website
www.caratherapeutics.comCara Therapeutics, Inc. (CARA) Latest News & Analysis
Latest News
Quick Summary
Cara Therapeutics, Inc. has announced a 1-for-3 reverse stock split of its common stock, approved by the Board of Directors, effective April 14, 2025.
Why It Matters
A 1-for-3 reverse stock split typically aims to boost the stock price and improve perceptions of financial stability, impacting shareholder value and market liquidity.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tvardi Therapeutics has merged to become a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing treatments for fibrosis-driven diseases targeting STAT3.
Why It Matters
The merger enhances Tvardi Therapeutics' market position and potential for growth, attracting investor interest in its innovative fibrosis treatments and Nasdaq listing.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Former Louisiana Attorney General Charles C. Foti, Jr. is investigating the merger between Cara Therapeutics, Inc. and Tvardi Therapeutics, Inc., focusing on the process behind the merger.
Why It Matters
The investigation into Cara Therapeutics' merger with Tvardi Therapeutics could indicate potential legal or regulatory issues, impacting shareholder value and market perception of the deal.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cara Therapeutics, Inc. will implement a 1-for-12 reverse stock split and reduce authorized shares from 200 million to 16.67 million, effective December 30, 2024.
Why It Matters
Cara Therapeutics' reverse stock split and reduction in authorized shares may impact share price, liquidity, and perceptions of financial health, influencing investor confidence and decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A proposed merger aims to form a Nasdaq-listed biopharmaceutical company focused on developing treatments targeting STAT3 for fibrosis-driven diseases.
Why It Matters
The merger could enhance market competitiveness and innovation in treating fibrosis, potentially attracting investment and driving stock value in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cara Therapeutics, Inc. - CARA
5 months ago
Quick Summary
Monteverde & Associates is investigating Cara Therapeutics (NASDAQ: CARA) due to its proposed merger with Tvardi Therapeutics, where CARA shareholders will own about 17% of the new entity.
Why It Matters
The investigation into Cara Therapeutics' merger could impact stock prices and shareholder value, highlighting potential legal risks and the company's strategic direction post-merger.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CARA Stock
What is Cara Therapeutics, Inc.'s (CARA) stock forecast for 2025?
Analyst forecasts for Cara Therapeutics, Inc. (CARA) are not currently available. The stock is trading at $15.96.
Is CARA stock a good investment in 2025?
According to current analyst ratings, CARA has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $15.96. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CARA stock?
Price predictions from Wall Street analysts for CARA are not currently available. The stock is trading at $15.96.
What is Cara Therapeutics, Inc.'s business model?
Cara Therapeutics generates revenue primarily through the development and commercialization of its lead product, KORSUVA, for treating chronic pruritus related to chronic kidney disease. The company also engages in licensing agreements with various pharmaceutical companies to expand the reach and application of its drug products in different markets, enhancing its potential revenue streams.
What is the highest forecasted price for CARA Cara Therapeutics, Inc.?
Price targets from Wall Street analysts for CARA are not currently available. The stock is trading at $15.96.
What is the lowest forecasted price for CARA Cara Therapeutics, Inc.?
Price targets from Wall Street analysts for CARA are not currently available. The stock is trading at $15.96.
What is the overall CARA consensus from analysts for Cara Therapeutics, Inc.?
The overall analyst consensus for CARA is neutral. Out of 4 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are CARA stock price projections?
Stock price projections, including those for Cara Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 1:02 PM UTC